A leading MNC in medical technology, Trivitron Healthcare has announced its strategic partnership with Diasorin Group, a global leader in immune segment. The two have partnered to enter immunodiagnostic market in India. Trivitron has already made its mark as a largest player in Indian IVD division, offering products in value and premium segments. Its partnership with Diasorin will complete Trivitrons offerings in the IVD product market by entering high growth immunodiagnostics market.
The DiaSorin- Trivitron partnership has formed the capital companies DiaSorin Trivitron Healthcare Private Limited, in which the parties have respectively 51% and 49% stakes. The company will directly operate in the Indian diagnostics market thus placing Trivitron as a leader in immunodiagnostic market over next 3 years.
Dr .G.S.K Velu, Founder and MD of Trivitron Group of Companies said, The joint venture with Diasorin is an important milestone for Trivitron to achieve market leadership position in the Indian IVD segment. We are confident that the venture will provide unique positioning for Trivitron. Trivitron has always excelled in building market leadership position in Immunoassay segment with the most innovative and extensive Immunoassay platform using CLIA/ ELISA/ RIA/MDx. Combining the strengths of Diasorin and Trivitron, in the next three years we attempt to reach leadership position in Indian Immunoassay segment.